SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, with community chatter focused on potential S&P 500 inclusion and the impact of future interest rate cuts. Bullish sentiment is high, with some expecting a significant price increase following earnings, while others are wary of a potential sell-off. The community is actively discussing potential earnings leaks and institutional buying patterns.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

GLXY is trending due to a recent $1B convertible note offering, leading to community debate on whether it's a strategic move for data center expansion or a dilution risk.  Despite strong earnings and expansion plans, investors are wary, drawing comparisons to other crypto firms and questioning the timing of the offering. Discussions also involve the company's potential ERCOT approval for its Texas data center campus.

Pump.fun

$PUMP is gaining traction within the Solana meme coin ecosystem, particularly on Pump.fun, with the community rallying around a 'We're All Gonna Make It' ($WAGMI) mentality. Traders are closely watching for meme rotations and potential breakouts, emphasizing community support and long-term holding.

ETHZilla Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palm Beach, FL.

ETHZilla Corp

ETHZilla Corporation

ETHZ is trending due to discussions around its stock repurchase program and the potential impact of Ethereum's price movements on the company's value. Community members are debating the company's strategy of selling ETH to buy back shares, with some seeing it as a smart move and others questioning its long-term viability. Broader market factors, including potential agreements between the U.S. and China, and the performance of other crypto-related stocks, are also influencing the conversation.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group (UNH) is trending as investors discuss upcoming earnings and potential market reactions. Community members are actively debating whether UNH will beat expectations, with some expressing nervousness about holding large positions through the release, while others analyze options strategies to capitalize on potential volatility. Broader discussions include the health sector's overall outlook and the impact of external factors like interest rate decisions.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is trending as investors debate its future ahead of upcoming earnings, with key concerns including potential dividend cuts, restructuring impacts, and the influence of Amazon. Community discussions revolve around whether UPS can maintain current levels or if a further decline is imminent. Sentiment is mixed, with some anticipating a significant move post-earnings while others point to the stock's long-term value and high dividend yield.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending following Rosenblatt's bullish report highlighting a major AI data center deal, positioning the company to challenge competitors in the AI infrastructure space. Community members are debating the significance of this move, with some questioning the hype and others pointing to Qualcomm's attractive valuation compared to peers. Option volume is elevated, suggesting increased investor interest.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies ($AVR) is trending as the company enrolls its first patients in the global PARADIGM pivotal trial of its DurAVR transcatheter heart valve. Despite the positive catalyst, the community is discussing the stock's recent price action and cash runway, with some speculating about future potential and others expressing concern over dilution.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as the stock flirts with all-time highs, fueled by optimism around strong iPhone demand and potential AI integration, with some analysts setting high price targets. Community discussions revolve around whether the current valuation is justified and the potential for a breakout, while others point to technical indicators suggesting a possible pullback. There's also chatter about Apple potentially partnering with SpaceX for Starlink satellite services in future iPhones.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

NTLA is trending due to a significant stock drop following a paused trial of its gene therapy nex-z after a patient experienced liver issues, sparking discussions around the severity and implications for the company's pipeline. The community is debating whether this is an overreaction and a buying opportunity, or a sign of deeper problems with the therapy, while analysts are adjusting price targets but largely maintaining buy ratings. Some traders anticipate a potential short squeeze given the high short interest and the company's cash reserves.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$MDCX On the verge of a breakout after that game-changing news hit this morning. 🚀2.05$ breakout is key !! 
 
🚨 Medicus Pharma ($MDCX) has officially closed the acquisition of Antev Ltd., bringing in Teverelix — a next-gen GnRH antagonist with blockbuster potential. 
 
Teverelix is positioned as a first-in-class treatment for acute urinary retention (AURr) and a best-in-class option for advanced prostate cancer patients with high cardiovascular risk. Together, these indications represent a $6B+ market opportunity. 
 
Adding to the excitement, veteran pharma executive Patrick J. Mahaffy (ex-Clovis, ex-Pharmion) has joined the board, strengthening leadership as $MDCX advances multiple Phase 2b trials. 
 
This deal supercharges Medicus’s pipeline and sets the stage for major near-term catalysts. 🚀📈 
 
Website: https://medicuspharma.com 
Communicated Disclaimer : https://tinyurl.com/2afx6epb 
Peers: $CRBP $SKYE $ADAG $COYA

Elmar Klimke

Our accomplished leadership team offers decades of cumulative experience progressing novel pharmaceuticals, biologics, and combination devices through clinical evaluation, regulatory approval, and successful market introduction.

Medicuspharma

Medicus Pharma |

This communication is sponsored content regarding Medicus Pharma ltd (NASDAQ/NYSE: $MDCX). I am not a financial advisor. Any statements or content I share are solely for entertainment, educational, and informational purposes, which of nothing posted should be taken as advice or direction. This post is part of a paid awareness campaign for Medicus Pharma ltd (NASDAQ/NYSE: $MDCX).

Google Docs

Disclaimer: Medicus pharma Ltd

StockTwits Web

Medicus Pharma Ltd

Corbus Pharmaceuticals Holdings Inc

Skye Bioscience Inc

Adagene Inc - ADR

Coya Therapeutics Inc

 On the verge of a breakout after that game-changing news hit this morning. 🚀2.05$ breakout is key !! 
 
🚨 Medicus Pharma (

) has officially closed the acquisition of Antev Ltd., bringing in Teverelix — a next-gen GnRH antagonist with blockbuster potential. 
 
Teverelix is positioned as a first-in-class treatment for acute urinary retention (AURr) and a best-in-class option for advanced prostate cancer patients with high cardiovascular risk. Together, these indications represent a $6B+ market opportunity. 
 
Adding to the excitement, veteran pharma executive Patrick J. Mahaffy (ex-Clovis, ex-Pharmion) has joined the board, strengthening leadership as 

 advances multiple Phase 2b trials. 
 
This deal supercharges Medicus’s pipeline and sets the stage for major near-term catalysts. 🚀📈 
 
Website: 